In the animal study, it is further demonstrated that inhibition of SPHK1 by PF-543 (a SPHK1 inhibitor) and/or inhibition of ATF4 by vemurafenib (a BRAF inhibitor to reduce ATF4 production) can inhibit the growth of TMZ-resistant GBM tumor. Here, ATF4 is linked to glioblastoma.